EGFR and neoplasm: Among these resistance mechanisms, relapsed tumours with EGFR T790M secondary mutation and those with SCLC transformation can be treated by “resistance mechanism-based” therapies, such as T790M-specific EGFR-TKIs in clinical trial settings5 or cytotoxic chemotherapy and radiation for SCLC3.